Cargando…
Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review
Articular cartilage has a limited capacity to repair following injury. Early intervention is required to prevent progression of focal traumatic chondral and osteochondral defects to advanced cartilage degeneration and osteoarthritis. Novel cell-based tissue engineering techniques have been proposed...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289291/ https://www.ncbi.nlm.nih.gov/pubmed/25606595 http://dx.doi.org/10.1186/s13075-014-0432-1 |
_version_ | 1782352085705031680 |
---|---|
author | Bornes, Troy D Adesida, Adetola B Jomha, Nadr M |
author_facet | Bornes, Troy D Adesida, Adetola B Jomha, Nadr M |
author_sort | Bornes, Troy D |
collection | PubMed |
description | Articular cartilage has a limited capacity to repair following injury. Early intervention is required to prevent progression of focal traumatic chondral and osteochondral defects to advanced cartilage degeneration and osteoarthritis. Novel cell-based tissue engineering techniques have been proposed with the goal of resurfacing defects with bioengineered tissue that recapitulates the properties of hyaline cartilage and integrates into native tissue. Transplantation of mesenchymal stem cells (MSCs) is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. MSCs are historically harvested through bone marrow aspiration, which does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. Biomaterial matrices are commonly used in conjunction with MSCs to aid cell delivery and support chondrogenic differentiation, functional extracellular matrix formation and three-dimensional tissue development. A number of specific transplantation protocols have successfully resurfaced articular cartilage in animals and humans to date. In the clinical literature, MSC-seeded scaffolds have filled a majority of defects with integrated hyaline-like cartilage repair tissue based on arthroscopic, histologic and imaging assessment. Positive functional outcomes have been reported at 12 to 48 months post-implantation, but future work is required to assess long-term outcomes with respect to other treatment modalities. Despite relatively positive outcomes, further investigation is required to establish a consensus on techniques for treatment of chondral and osteochondral defects with respect to cell source, isolation and expansion, implantation density, in vitro precultivation, and scaffold composition. This will allow for further optimization of MSC proliferation, chondrogenic differentiation, bioengineered cartilage integration, and clinical outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-014-0432-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4289291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42892912015-01-11 Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review Bornes, Troy D Adesida, Adetola B Jomha, Nadr M Arthritis Res Ther Review Articular cartilage has a limited capacity to repair following injury. Early intervention is required to prevent progression of focal traumatic chondral and osteochondral defects to advanced cartilage degeneration and osteoarthritis. Novel cell-based tissue engineering techniques have been proposed with the goal of resurfacing defects with bioengineered tissue that recapitulates the properties of hyaline cartilage and integrates into native tissue. Transplantation of mesenchymal stem cells (MSCs) is a promising strategy given the high proliferative capacity of MSCs and their potential to differentiate into cartilage-producing cells - chondrocytes. MSCs are historically harvested through bone marrow aspiration, which does not require invasive surgical intervention or cartilage extraction from other sites as required by other cell-based strategies. Biomaterial matrices are commonly used in conjunction with MSCs to aid cell delivery and support chondrogenic differentiation, functional extracellular matrix formation and three-dimensional tissue development. A number of specific transplantation protocols have successfully resurfaced articular cartilage in animals and humans to date. In the clinical literature, MSC-seeded scaffolds have filled a majority of defects with integrated hyaline-like cartilage repair tissue based on arthroscopic, histologic and imaging assessment. Positive functional outcomes have been reported at 12 to 48 months post-implantation, but future work is required to assess long-term outcomes with respect to other treatment modalities. Despite relatively positive outcomes, further investigation is required to establish a consensus on techniques for treatment of chondral and osteochondral defects with respect to cell source, isolation and expansion, implantation density, in vitro precultivation, and scaffold composition. This will allow for further optimization of MSC proliferation, chondrogenic differentiation, bioengineered cartilage integration, and clinical outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-014-0432-1) contains supplementary material, which is available to authorized users. BioMed Central 2014-09-26 2014 /pmc/articles/PMC4289291/ /pubmed/25606595 http://dx.doi.org/10.1186/s13075-014-0432-1 Text en © Bornes et al.; licensee BioMed Central Ltd. 2014 The licensee has exclusive rights to distribute this article, in any medium, for 6 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Bornes, Troy D Adesida, Adetola B Jomha, Nadr M Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title | Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title_full | Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title_fullStr | Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title_full_unstemmed | Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title_short | Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
title_sort | mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289291/ https://www.ncbi.nlm.nih.gov/pubmed/25606595 http://dx.doi.org/10.1186/s13075-014-0432-1 |
work_keys_str_mv | AT bornestroyd mesenchymalstemcellsinthetreatmentoftraumaticarticularcartilagedefectsacomprehensivereview AT adesidaadetolab mesenchymalstemcellsinthetreatmentoftraumaticarticularcartilagedefectsacomprehensivereview AT jomhanadrm mesenchymalstemcellsinthetreatmentoftraumaticarticularcartilagedefectsacomprehensivereview |